Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer
Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
Interventions
- OTHER: laboratory biomarker analysis
Sponsor
University Health Network, Toronto
Collaborators